{"organizations": [], "uuid": "735452da1c93caf24414ce59f4077bbad3162d0e", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 12, "shares": 12, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "https://www.reuters.com/finance/markets/europe", "section_title": "European Stock Market News | Reuters.com", "url": "https://www.reuters.com/article/brief-novartis-says-kymriah-receives-sec/brief-novartis-says-kymriah-receives-second-fda-approval-idUSASO00043N", "country": "US", "domain_rank": 408, "title": "BRIEF-Novartis says Kymriah receives second FDA approval", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 1.0, "site_type": "news", "published": "2018-05-02T04:33:00.000+03:00", "replies_count": 0, "uuid": "735452da1c93caf24414ce59f4077bbad3162d0e"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-novartis-says-kymriah-receives-sec/brief-novartis-says-kymriah-receives-second-fda-approval-idUSASO00043N", "ord_in_thread": 0, "title": "BRIEF-Novartis says Kymriah receives second FDA approval", "locations": [], "entities": {"persons": [{"name": "kymriah", "sentiment": "negative"}], "locations": [{"name": "us", "sentiment": "none"}], "organizations": [{"name": "novartis ag", "sentiment": "negative"}, {"name": "fda", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 1 (Reuters) - Novartis AG:\n* KYMRIAHÂ® (TISAGENLECLEUCEL), FIRST-IN-CLASS CAR-T THERAPY FROM NOVARTIS, RECEIVES SECOND FDA APPROVAL TO TREAT APPROPRIATE R/R PATIENTS WITH LARGE B-CELL LYMPHOMA\n* US FOOD AND DRUG ADMINISTRATION APPROVED KYMRIAH SUSPENSION FOR INTRAVENOUS INFUSION FOR ITS SECOND INDICATION\n* KYMRIAH DEMONSTRATED OVERALL RESPONSE RATE OF 50%, WITH MEDIAN DURATION OF RESPONSE NOT YET REACHED AT TIME OF DATA CUT-OFF\n* KYMRIAH IS NOT INDICATED FOR TREATMENT OF PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-02T04:33:00.000+03:00", "crawled": "2018-05-02T07:18:27.000+03:00", "highlightTitle": ""}